Skip to content
Open access

Age-Related Decline in Anterior Cingulate and Medial Prefrontal Metabolism in Nonneurodegenerative Patients: An 18 F-FDG PET Study

Aug 2026 · World Journal of Nuclear Medicine · 0 citations · 29 references

TL;DR

Investigating age-related regional metabolic changes in individuals undergoing brain FDG PET imaging without evidence of neurodegenerative disease supports region-specific metabolic vulnerability during normal aging while highlighting substantial interindividual variability in cerebral glucose metabolism.

Abstract

Abstract Objective 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) is widely used to evaluate patients with cognitive complaints, particularly to differentiate neurodegenerative disorders. However, memory impairment may arise from various nonneurodegenerative conditions, including metabolic, psychiatric, and nutritional factors. Age-related physiological changes in cerebral glucose metabolism may further complicate image interpretation and lead to potential diagnostic misclassification. This study aimed to investigate age-related regional metabolic changes in individuals undergoing brain FDG PET imaging without evidence of neurodegenerative disease. Methods A retrospective analysis was conducted on 77 patients (aged 19–89 years) who underwent brain FDG PET imaging between August 2023 and January 2025. All subjects had comprehensive clinical and neuropsychological evaluations, excluding neurodegenerative pathology. Quantitative analysis was performed using Cortex ID software on a dedicated workstation. Mean standardized uptake values were calculated for the anterior cingulate/medial prefrontal (ACC/MF), posterior cingulate/precuneus (PCC/PC), parietal, and temporal cortical regions. Correlation analyses were performed to assess the relationship between age and regional FDG uptake. Results The study cohort consisted of 35 women (mean age: 62.48 ± 16.61 years) and 42 men (mean age: 69.92 ± 10.91 years). Increasing age was significantly associated with reduced FDG uptake in key frontal and cingulate regions, including the left PCC/PC cortex ( R 2  = 0.05624, p  = 0.0378), right ACC/MF cortex ( R 2  = 0.05573, p  = 0.0387), and left ACC/MF cortex ( R 2  = 0.06828, p  = 0.0217). However, the effect sizes were modest, indicating that age explained only a limited proportion of the variability in regional FDG uptake, while the scatter plots revealed considerable interindividual variability despite the overall age-related trend. No significant associations were observed in other cortical regions. Conclusion In individuals without neurodegenerative disease, advancing age is associated with a selective decline in glucose metabolism within the ACC and MF, with a weaker age-related effect in the left PCC/PC region. These findings support region-specific metabolic vulnerability during normal aging while highlighting substantial interindividual variability in cerebral glucose metabolism. Consequently, age-adjusted interpretation of FDG PET is essential. Borderline frontal hypometabolism should not be interpreted in isolation as evidence of frontotemporal dementia or frontal-variant Alzheimer's disease but should always be integrated with the patient's clinical presentation and neuropsychological assessment to minimize false-positive diagnoses.

Read PDF

Similar papers

Aug 2026

Multimodal PET Imaging Unveils Early Metabolic Compensation Mechanisms and Dopaminergic Degeneration in Parkinson’s Disease

Multimodal PET imaging reveals dynamic interactions between cerebral glucose metabolism and dopaminergic degeneration in Parkinson’s disease, highlighting cerebellar-pontine hypermetabolism as a compensatory response to nigrostriatal degeneration.

Shuang Li, Wei-Zhao Lu, Shao-Zhen Yan et al. · 0 citations
Sep 2026

Change in routine PET-derived frontal metabolism is associated with worsening depressive symptoms during treatment for head and neck cancer: a longitudinal cohort study.

Declining relative FDG uptake in a predefined Broca-region ROI accompanied worsening depressive symptoms during HNC treatment, supporting prospective evaluation of routine PET as a potential source of psychiatric symptom-related information in patients receiving oncological care.

Antonis Tsionis, Efthymios Kyrodimos, Sofia Chatziioannou et al. · 0 citations
Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · 0 citations
Open access Oct 2026

Associations Between Language Performance and Glucose Uptake Rate Using Dynamic FDG-PET in Focal Epilepsy

Objective: Neuropsychological assessment and metabolic imaging inform presurgical planning for patients with focal epilepsy, but conventional static FDG-PET (sPET) has limitations in identifying disruptions in dominant hemisphere networks. Dynamic 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (dFDG-PE...

R. Smetana, P. Chernyavskiy, Bijoy Kundu et al. · 0 citations
Open access Oct 2026

Association Between Neuropsychological Test Performance and Neuroimaging Findings in Cognitive Impairment: A Retrospective Cohort Study.

BACKGROUND Structural magnetic resonance imaging (MRI) and [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) provide different information about cognitive impairment, but the additional contribution of FDG-PET beyond MRI across cognitive outcomes remains unclear. This study examined associations between ne...

Mesut Dorukoğlu, D. Evyapan, C. Eraslan · 0 citations
Sep 2026

Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease.

BACKGROUND Understanding the heterogeneity of Parkinson's disease (PD) is essential to guide patient care, prognosis, and treatment. OBJECTIVE We used 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), 18F-N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) PET, and Subtype...

Jung Hyun Lee, H. K. Na, Sung Jun Ahn et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.